4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
4DMT (Nasdaq: FDMT) entered an exclusive license agreement with Otsuka to develop and commercialize 4D-150 for wet AMD and DME across the greater Asia-Pacific region, including Japan.
Key terms include an $85 million upfront cash payment, an expected ≥$50 million of cost sharing over three years for global development, up to $336 million in regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains development and commercialization rights outside APAC and will continue to lead global Phase 3 activities; APAC sites for 4FRONT-2 are expected to open by year-end, with Japan sites expected in January 2026.
4DMT (Nasdaq: FDMT) ha stipulato un accordo di licenza esclusiva con Otsuka per sviluppare e commercializzare 4D-150 per AMD umida e DME nell’ampia regione Asia-Pacifico, inclusa il Giappone.
I termini chiave includono un pagamento in contanti upfront di $85 milioni, una prevista condivisione dei costi di almeno ≥$50 milioni su tre anni per lo sviluppo globale, fino a $336 milioni in traguardi regolatori e commerciali, e royalty a doppia cifra a scalare sul netto delle vendite nei territori di Otsuka. 4DMT mantiene i diritti di sviluppo e commercializzazione al di fuori dell’APAC e continuerà a guidare le attività globali di Phase 3; si prevede l’apertura di siti APAC per 4FRONT-2 entro fine anno, con siti in Giappone previsti a gennaio 2026.
4DMT (Nasdaq: FDMT) firmó un acuerdo de licencia exclusiva con Otsuka para desarrollar y comercializar 4D-150 para AMD húmeda y DME en la amplia región Asia-Pacífico, incluido Japón.
Los términos clave incluyen un pago en efectivo inicial de $85 millones, un esperado ≥$50 millones de compartición de costos durante tres años para el desarrollo global, hasta $336 millones en hitos regulatorios y comerciales, y regalías escalonadas de dos dígitos sobre las ventas netas en los territorios de Otsuka. 4DMT retiene los derechos de desarrollo y comercialización fuera de APAC y continuará liderando las actividades globales de Fase 3; se espera que abran sitios APAC para 4FRONT-2 antes de fin de año, con sitios en Japón previstos para enero 2026.
4DMT (나스닥: FDMT)는 일본을 포함한 광범위한 아시아-태평양 지역에서 습성 AMD 및 DME에 대해 4D-150을 개발·상용화하기 위한 Otsuka와의 독점 라이선스 계약을 체결했습니다.
주요 조건으로는 $85 백만의 선지급 현금 지급, 전 세계 개발을 위한 3년간 최소 ≥$50 백만의 비용 분담 및 예측, 규제 및 상업상의 마일스톤으로 최대 $336 백만, 그리고 Otsuka의 지역에서 순매출에 대한 계층형 두 자릿수 로열티가 있습니다. 4DMT는 APAC 외 지역의 개발 및 상용화 권리를 보유하며 글로벌 3상 활동을 계속 주도할 예정이며; 4FRONT-2의 APAC 사이트는 올해 말까지 개설될 예정이고 일본 사이트는 2026년 1월에 예정되어 있습니다.
4DMT (Nasdaq : FDMT) a conclu un accord de licence exclusive avec Otsuka pour développer et commercialiser 4D-150 pour la DME humide et AMD dans la vaste région Asie-Pacifique, y compris le Japon.
Les principaux termes comprennent un paiement initial en espèces de 85 millions de dollars, un partage des coûts prévu d’au moins ≥50 millions de dollars sur trois ans pour le développement mondial, jusqu’à 336 millions de dollars en jalons réglementaires et commerciaux, et des redevances à deux chiffres par paliers sur les ventes nettes dans les territoires d’Otsuka. 4DMT conserve les droits de développement et de commercialisation en dehors de l’APAC et poursuivra la conduite des activités mondiales de la Phase 3 ; les sites APAC pour 4FRONT-2 devraient ouvrir d’ici la fin de l’année, et les sites au Japon sont prévus en janvier 2026.
4DMT (Nasdaq: FDMT) hat mit Otsuka eine exklusive Lizenzvereinbarung zur Entwicklung und Vermarktung von 4D-150 für feuchte AMD und DME im gesamten größeren Asia-Pacific-Raum, einschließlich Japan, getroffen.
Zu den wichtigsten Konditionen gehören eine sofortige Bargeldzahlung von $85 Millionen, voraussichtlich ≥$50 Millionen an Kostenbeteiligung über drei Jahre für die globale Entwicklung, bis zu $336 Millionen an behörden- und kommerziellen Meilensteinen sowie gestaffelte zweistellige Lizenzgebühren auf den Nettoumsatz in Otsukas Gebieten. 4DMT behält Entwicklungs- und Vermarktungsrechte außerhalb APAC und wird die globalen Phase-3-Aktivitäten weiterhin leiten; APAC-Standorte für 4FRONT-2 sollen bis zum Jahresende eröffnet werden, Japan-Standorte voraussichtlich im Januar 2026.
4DMT (ناسداك: FDMT) أبرمت اتفاقية ترخيص حصرية مع أوساكا لتطوير وتسويق 4D-150 ل AMD الرطب و DME عبر منطقة آسيا-المحيط الهادئ الكبرى، بما في ذلك اليابان.
تشمل الشروط الرئيسية دفعة نقدية مقدمة قدرها $85 مليون، وتوقع ≥$50 مليون من مشاركة التكاليف على مدى ثلاث سنوات للتطوير العالمي، وحتى $336 مليون في معالم تنظيمية وتجارية، ومزايا ملكية بنسب عائدات مرتفعة على صافي المبيعات في مناطق أوساكا. تحتفظ 4DMT بحقوق التطوير والتسويق خارج APAC وستواصل قيادة أنشطة المرحلة 3 العالمية؛ من المتوقع أن تفتح مواقع APAC لـ 4FRONT-2 بنهاية السنة، مع مواقع في اليابان متوقعة في يناير 2026.
- $85M upfront cash payment to 4DMT
- Expected ≥$50M cost sharing over three years for development
- Up to $336M in potential regulatory and commercial milestones
- 4DMT retains rights outside APAC (U.S., Latin America, Europe)
- APAC Phase 3 sites for 4FRONT-2 expected to open by year-end; Japan in Jan 2026
- 4DMT granted Otsuka exclusive APAC rights, ceding direct commercial control in those markets
- Otsuka will lead all regulatory and commercialization activities in APAC, limiting 4DMT’s commercial execution in those territories
Insights
Upfront cash and cost sharing materially de‑risks near‑term funding for global Phase 3 and expands APAC commercialization reach.
4DMT secures
The business mechanism is straightforward: immediate non‑dilutive funding and expense sharing support ongoing global Phase 3 and pre‑commercial work, while Otsuka provides local regulatory know‑how and commercial infrastructure in APAC markets. Key dependencies and risks remain limited to items disclosed: successful Phase 3 execution, regional regulatory approvals, and effective coordination between the global sponsor role and the regional licensee. Monitor the opening of APAC clinical sites by end of year and Japan sites in
- 4DMT to receive
$85 million upfront cash payment and expect to receive at least$50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration - Up to
$336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka’s territories - Proceeds and cost sharing expected to support global Phase 3 clinical trial in DME and pre-commercial activities
EMERYVILLE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a strategic partnership with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) in the greater Asia-Pacific (APAC) region including Japan.
The strategic partnership combines 4DMT’s expertise in AAV genetic medicine, development in retina and manufacturing with Otsuka’s strong development expertise, regulatory experience and commercial infrastructure across APAC markets. Together, the companies aim to receive 4D-150 marketing approval and commercialization in major markets globally. 4D-150 is a potentially transformative backbone therapy providing durable benefit in retinal vascular diseases such as wet AMD and DME, which are among the leading causes of blindness in the world.
Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases, including wet AMD and DME, in Japan, China, Australia and other Asia-Pacific markets. Otsuka will lead all regulatory and commercialization activities in its licensed territories. 4DMT will continue to lead all Phase 3 clinical activities globally, including within the APAC region. APAC clinical sites in 4FRONT-2, the global Phase 3 study in wet AMD, are expected to open by end of year, with Japan sites expected to open in January 2026.
4DMT will receive an upfront cash payment of
“We are thrilled to announce this strategic partnership with Otsuka, a leading global pharmaceutical company with a strong presence in the APAC region, reflecting our shared long-term commitment to improving outcomes for patients with retinal vascular diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “This partnership is a key pillar of our global strategy, with 4DMT continuing to lead Phase 3 clinical trial and manufacturing activities globally, in addition to pre-commercial and commercial activities outside the APAC region.”
“APAC represents a large and underserved retina market, with a high prevalence of wet AMD and DME. Navigating the region’s regulatory and patient-access complexities requires a strong local partner, and we expect Otsuka’s deep presence and expertise to accelerate both development of and access to 4D-150,” said Chris Simms, Chief Commercial Officer of 4DMT. “Partnering with Otsuka extends the global reach of 4D-150 and ensures that patients in regions with limited access to innovative therapies may ultimately benefit from its potential to deliver durable treatment burden reductions and vision preservation.”
“Otsuka has created new value that contributes to the well-being of patients in Japan and around the world through both in-house and collaborative research,” said Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. “By introducing 4D-150 to the markets in Japan, and elsewhere in Asia and Oceania, we aim to help prevent vision loss through a single, potentially lifelong administration.”
About 4D-150
4D-150 is a potential backbone therapy designed to provide multi-year, and potentially lifelong, sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal AAV vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and DME which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision.
About Wet AMD
Wet AMD, or wet age-related macular degeneration, is a highly prevalent disease, with more than 4 million individuals expected to be affected in the next five years in certain major markets, including the U.S., the EU and Japan. The disease also has a high incidence, with 200,000 individuals estimated to be newly diagnosed every year in the U.S. alone. Wet AMD is a type of macular degeneration in which abnormal blood vessels grow into the macula (macular neovascularization or MNV), the central area of the retina. MNV causes swelling and edema of the retina, bleeding and scarring, leading to visual distortion and reduced visual acuity. The proliferation and leakage of abnormal blood vessels is stimulated by VEGF. This process distorts and, without treatment, can potentially destroy central vision and may progress to blindness.
About DME
DME, or diabetic macular edema, is a complication of diabetic retinopathy and is a highly prevalent disease with significant unmet medical need and poor treatment adherence. It is estimated that there are approximately one million individuals with DME in the U.S. according to published data. DME is characterized by inflammation swelling in the macula due to leakage from blood vessels, which can lead to vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-16 weeks, although patient compliance with therapy is poor and results in high unmet medical need.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, clinical development, marketing, and commercialization of our product candidates, including 4D-150, the potential benefits of the strategic partnership with Otsuka, the amount of any potential cost sharing or milestone payments pursuant to the Company’s agreement with Otsuka, timing of opening of APAC clinical sites, and our use of proceeds. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q filed on August 11, 2025, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
What did 4DMT (FDMT) announce about 4D-150 in Asia-Pacific on October 31, 2025?
How much milestone and royalty potential did 4DMT secure in the Otsuka APAC deal (FDMT)?
Will 4DMT still run Phase 3 trials for 4D-150 after the Otsuka license (FDMT)?
When will APAC and Japan clinical sites open for 4DMT’s 4FRONT-2 Phase 3 study (FDMT)?
Which territories does 4DMT keep commercialization rights for 4D-150 after the Otsuka deal (FDMT)?
